3 news items
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
CHRS
9 May 24
, consistent with our overarching mission to become a sustainable and growing oncology company improving outcomes for cancer patients
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
CHRS
13 Mar 24
in transforming the Company's business model and product portfolio for long-term sustainable growth," said Denny Lanfear, Coherus' Chairman and Chief Executive
Coherus Completes Divestiture of Ophthalmology Franchise
CHRS
4 Mar 24
our efforts to become a sustainable and growing oncology business." Coherus' oncology assets include the UDENYCA® (pegfilgrastim-cbqv
- Prev
- 1
- Next